Literature DB >> 8764969

Negative inotropic actions of nitric oxide require high doses in rat cardiac muscle.

R P Wyeth1, K Temma, E Seifen, R H Kennedy.   

Abstract

Initial experiments were designed to determine if vasoactive concentrations of nitric oxide (NO) alter contractility in rat heart. Contractile function was monitored in left atrial and papillary muscles (30 degrees C; paced at 0.5 Hz) during cumulative addition of 3-morpholino-sydnonimine-HCl(SIN-1), an agent that releases NO. At concentrations between 10(-7) and 10(-4) M (NO concentrations of approximately 10(-8)- 3 x 10(-7) M), SIN-1 did not affect contractility in either tissue. Similarly, 10(-4) M SIN-1 did not alter the positive inotropic responses to isoproterenol or increasing extracellular [Ca+2] ([Ca+2]o). To obtain higher concentrations of NO, additional studies were conducted using authentic NO. NO-saturated stock solutions and a corresponding control solvent were adjusted to pH 1.6 with HCl. Dose-dependent effects of NO were examined by adding aliquots of the stock solutions (or control solvent) to the bathing solution. At final concentrations of 1 x 10(-5)- 5 x 10(-4) M, NO produced transient, concentration-dependent decreases in contractility that were paralleled by reductions in buffer pH. Control solvent elicited similar reductions in pHo and transient decreases in contractility; however, the negative inotropic action elicited by the NO-containing solution was approximately 20% greater than that observed in control conditions. These data demonstrate that only high concentrations of NO depress contractility in isolated rat cardiac muscle, and suggest that this effect is mediated by both acidosis and a pHo-independent mechanism.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8764969     DOI: 10.1007/s004240050185

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  31 in total

Review 1.  Endothelium, endocardium, and cardiac contraction.

Authors:  A H Henderson; M J Lewis; A M Shah; J A Smith
Journal:  Cardiovasc Res       Date:  1992-04       Impact factor: 10.787

2.  Factors released from endocardium of the ferret and pig modulate myocardial contraction.

Authors:  J A Smith; A M Shah; M J Lewis
Journal:  J Physiol       Date:  1991-08       Impact factor: 5.182

Review 3.  Effects of changes of pH on the contractile function of cardiac muscle.

Authors:  C H Orchard; J C Kentish
Journal:  Am J Physiol       Date:  1990-06

4.  Opposite effects of cyclic GMP and cyclic AMP on Ca2+ current in single heart cells.

Authors:  H C Hartzell; R Fischmeister
Journal:  Nature       Date:  1986 Sep 18-24       Impact factor: 49.962

5.  Models of the diffusional spread of nitric oxide: implications for neural nitric oxide signalling and its pharmacological properties.

Authors:  J Wood; J Garthwaite
Journal:  Neuropharmacology       Date:  1994-11       Impact factor: 5.250

6.  Relationship between myoglobin contents and increases in cyclic GMP produced by glyceryl trinitrate and nitric oxide in rabbit aorta, right atrium and papillary muscle.

Authors:  T Ishibashi; M Hamaguchi; K Kato; T Kawada; H Ohta; H Sasage; S Imai
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-05       Impact factor: 3.000

7.  8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes.

Authors:  A M Shah; H A Spurgeon; S J Sollott; A Talo; E G Lakatta
Journal:  Circ Res       Date:  1994-05       Impact factor: 17.367

8.  Nitric oxide donor SIN-1 inhibits mammalian cardiac calcium current through cGMP-dependent protein kinase.

Authors:  G M Wahler; S J Dollinger
Journal:  Am J Physiol       Date:  1995-01

9.  Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation.

Authors:  P F Méry; C Pavoine; L Belhassen; F Pecker; R Fischmeister
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

10.  Nitric oxide regulates the calcium current in isolated human atrial myocytes.

Authors:  M Kirstein; M Rivet-Bastide; S Hatem; A Bénardeau; J J Mercadier; R Fischmeister
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

View more
  7 in total

1.  Peroxynitrite is a positive inotropic agent in atrial and ventricular fibres of the frog heart.

Authors:  J M Chesnais; R Fischmeister; P F Mery
Journal:  J Physiol       Date:  1999-12-01       Impact factor: 5.182

2.  Positive and negative inotropic effects of NO donors in atrial and ventricular fibres of the frog heart.

Authors:  J M Chesnais; R Fischmeister; P F Méry
Journal:  J Physiol       Date:  1999-07-15       Impact factor: 5.182

3.  Inhibition of sarcoplasmic reticular function by chronic interleukin-6 exposure via iNOS in adult ventricular myocytes.

Authors:  Xin-Wen Yu; Qian Chen; Richard H Kennedy; Shi J Liu
Journal:  J Physiol       Date:  2005-04-21       Impact factor: 5.182

4.  Nitric oxide effects depend on different mechanisms in different regions of the rat heart.

Authors:  Kursat Derici; Ufuk Samsar; Emine Demirel-Yilmaz
Journal:  Heart Vessels       Date:  2011-02-11       Impact factor: 2.037

5.  Failure of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) to inhibit soluble guanylyl cyclase in rat ventricular cardiomyocytes.

Authors:  J W Wegener; E I Closs; U Förstermann; H Nawrath
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 6.  Nitric oxide control of cardiac function: is neuronal nitric oxide synthase a key component?

Authors:  Claire E Sears; Euan A Ashley; Barbara Casadei
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2004-06-29       Impact factor: 6.237

7.  Nitric oxide modulates cardiomyocyte pH control through a biphasic effect on sodium/hydrogen exchanger-1.

Authors:  Mark A Richards; Jillian N Simon; Ruichong Ma; Aminah A Loonat; Mark J Crabtree; David J Paterson; Richard P Fahlman; Barbara Casadei; Larry Fliegel; Pawel Swietach
Journal:  Cardiovasc Res       Date:  2020-10-01       Impact factor: 10.787

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.